SPIMACO signs an agreement with Abdi Ibrahim company:

27/08/2013 Argaam

SPIMACO Pharmaceutical Company announced today on tadawul signing 7 years renewable agreement with Turkey-based Abdi Ibrahim Company (GSK) to market and distribute 5 products the Turkish market.

These products are expected to be offered in the Turkish  market during the first half of 2014 and expected to generate SAR 112m sales revenues per annum to SPIMACO.

Comments {{getCommentCount()}}

Be the first to comment

{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
{{comment.Replies.length}}
تعديل
loader Train
Report
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.